Skip to content
Unrated Drug recall · FDA · Published January 31, 2023

Biocon Pharma Posaconazole Tablets Recall: High Impurities Risk

Biocon Pharma recalls 100mg Posaconazole Delayed-Release Tablets with high impurities. Affected lots expire Sep 2023-Dec 2023. Stop using if you have these specific batches.

🇺🇸 FDA recall #D-0268-2023DrugBiocon Pharma ›
Take action

Contact the company

Recalling firmBIOCON PHARMA INC485 HWY 1 (S) · ISELIN, NJ 08830
✎ GovInfoNow plain-language explainer

Biocon Pharma is recalling 100mg Posaconazole Delayed-Release Tablets due to high impurities that could cause harm. This recall affects specific batches with expiration dates through September 2023 and December 2023. The product is prescription-only and must be stopped if you have the affected lots. Read more at govinfonow.com/recall/33973-biocon-pharma-posaconazole-tablets-recall-high-impurities-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/33973-biocon-pharma-posaconazole-tablets-recall-high-impurities-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0268-2023

Cite this page

“Biocon Pharma Posaconazole Tablets Recall: High Impurities Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/33973-biocon-pharma-posaconazole-tablets-recall-high-impurities-risk. Based on FDA recall #D-0268-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0268-2023%22&limit=1).

The FDA announced on Jan. 31, 2023, that Biocon Pharma Inc. voluntarily recalled Posaconazole Delayed-Release Tablets due to failed impurity specifications. The recall affects 3,665 bottles distributed nationwide.

How to tell if you have it

  • Brand: Biocon Pharma
  • Product: Posaconazole Delayed-Release Tablets, 100 mg, 60-count bottle
  • NDC: 70377-038-11
  • Lot codes: BF21003163 (Exp. Sep-2023), BF21003246 (Exp. Sep-2023), BF21003161 (Exp. Sep-2023), BF21004742 (Exp. Dec-2023), BF22003359 (Exp. Sep-2025)
  • Quantity: 3,665 bottles
  • Distribution: Nationwide in the USA

The hazard

According to the FDA, the recalled tablets contain high out-of-specification degradation results. The agency classified this as a Class II recall.

Context

GovInfoNow's records show Biocon Pharma Inc. has one other recall on record since March 17, 2025, for Atorvastatin 40mg Tablets due to failed dissolution specifications. Other recent recalls of similar products include Unichem Bisoprolol/Hydrochlorothiazide Tablets Recall (Jan. 21, 2026), Sagent Busulfan Injection Recall (May 4, 2026), and Appco Pharma Recalls Prazosin Capsules Due to Nitrosamine Impurity Risk (March 27, 2026).

How to tell if you have this one

Check the batch number on the product label. Affected batches include BF21003163, BF21003246, BF21003161, BF21004742, and BF22003359. The product expires by September 2023, December 2023, or September 2025.

  • Brand
    Biocon Pharma
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Batch Number

    Look for the batch number on the product label to determine if it is one of the affected lots.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 17 months after the firm started it.

1. Firm started the recall: Jan 31, 202312. FDA classified it Class II: Feb 14, 202323. Published in FDA’s Enforcement Report: Feb 15, 202334. FDA terminated the recall: Jun 21, 2024420232024
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0268-2023 (January 31, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0268-2023 to see it in context.
  • Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA